IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (AP20 Rec'd PCT/PTO 21 JUN 2006

In re Applicant:

Sobhi SAUOB, et al

Serial No.:

National Phase of PCT/IL2004/001155

Filed:

Herewith

For:

Compositions Derived From Portulaca Oleracea L. And Methods Of Using Same For Modulating Blood Glucose Levels

Examiner:

Not Yet Assigned

Mail Stop Amedment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: Not Yet Assigned

Attorney

Docket: 32102

## INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Mutha O. Mopula

Martin D. Moynihan

Registration No. 40,338

Dated: June 21, 2006

## AP20 Rec'd PCT/PTO 21 JUN 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pa	perwork	Reduction Act of 1995, no persons a	are required to	respond to a co	llection of information unless it contains	a valid ON	AB control number.	
		Substitute for form 14400/F	T0		Complete if Known			
Substitute for form 1449A/PTO					Application Number	National Phase of		
INFORMATION DISCLOSURE						PGT	112004/551853759	
STATEMENT BY APPLICANT				NT	Filing Date	Here	Herewith	
(use as many sheets as necessary)					First Named Inventor	Sobi	Sobhi SAUOB	
					Art Unit		Not Yet Assigned	
					Examiner Name	Not	Not Yet Assigned	
Sheet		1	of	2	Attorney Docket Number	3210	)2	
			U.S.	PATENT	DOCUMENTS			
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2 (if known)</sup>					rigures Appear	
	ļ							
	ļ							
	1							
	†							
	<del> </del>							
	<del> </del>							
	-							
	<del>                                     </del>							

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Documents  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	JP 63-208531	08-30-1988	Kin et al.		
	2	PCT WO 00/00211	06-6-2000	Garti et al.		${\mathbb H}$
						$\blacksquare$
Examiner Signature		/Qiuwen Mi/		Date Considered	03/28/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IAP20 Rec'd PCT/PTO 21 JUN 2006

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known.

Der National Phase of PCT/IL2004/0011 Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE <u>Herewith</u> Filing Date STATEMENT BY APPLICANT First Named Inventor Sobhi SAUOB Not Yet Assigned Group Art Unit (use as many sheets as necessary) Not Yet Assigned **Examiner Name** Attorney Docket Number 32102 2 Sheet 2 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T<sup>2</sup> No.1 **Initials** publisher, city and/or country where published. Eskander et al. "Hypoglycaemic and Hyperinsulinemic Effects of Some Egyptian 3 Herbs Used for the Treatment of Diabetes Mellitus (Type II) in Rats", Egyptian Journal of Pharmacological Science, 36(1-6): 331-341, 1995. P.331, 333, 335, 337.

Signature /Qiowen Mi/ Considered 03/28/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.